Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
The Supreme Court on Monday granted a further time of six weeks to the Centre to file its response on a writ petition highlighting the alleged illegal clinical trials of untested drugs being conducted by pharmaceutical firms on adults, children and even mentally ill persons. A Bench of Justices R.M. …
Tuesday's meeting to examine the pricing policy prepared by ministry of chemicals & fertilisers On Tuesday, a group of ministers (GoM) led by agriculture minister Sharad Pawar will examine the proposed National Pharmaceutical Pricing Policy (NPPP) prepared by the ministry of chemicals and fertilisers. The key issue is to vet …
In January 2005, drug product patent protection was reintroduced in India to comply with the agreement on Trade Related Aspects of Intellectual Property Rights. How are the multinational pharmaceutical companies responding to the new policy environment? Is India likely to see monopolisation of the industry and high prices, which was …
A high-level panel constituted by the health ministry is likely to suggest a system of negotiated prices for all new medicines approved in the country. The proposal to control the launch prices of drugs comes at a time when the chemicals and fertilisers ministry, responsible for deciding medicine prices, is …
An AIIMS study has found that dhaniya or coriander plays a significant therapeutic role in managing rheumatoid arthritis (RA). The study, published in the latest issue of the Indian Journal of Medical Research, evaluated the anti-arthritic activity of the herb among rats. Dhaniya or Coriandrum sativum was found to inhibit …
DoP to continue with production cost-based model for pricing of essential drugs The department of pharmaceuticals has decided to abandon its controversial “industry-friendly” proposal to cap retail prices of essential medicines at the average price of the three best-selling brands and stick with the cost of production as the parameter. …
The alleged illegal clinical trials of untested drugs by pharmaceutical firms in the country, has come under the judicial scrutiny with the Supreme Court seeking the Centre's stand on a plea for an independent probe into it. A bench of justices R.M. Lodha and H.L. Gokhale issued notices to the …
In a landmark move, the Indian Patent Office announced on Monday that it has issued its first compulsory license to a domestic generic drug-maker. The decision effectively ends German pharmaceutical company Bayer AG's monopoly over an anti-cancer drug and authorises the production of a low-cost version for the Indian market.
Move may weigh on other similar tie-ups with Indian cos, Biocon shares plunge 6.3% to . 250.8 on BSE. Pfizer Inc has terminated a deal to sell Biocon’s insulin products globally, dealing the Indian company a blow and calling into question similar tieups because of a change in the US …
The government today asserted India would invoke the flexibility it had under the WTO agreement on Trade Related Intellectual Property Rights (TRIPs) for compulsory licensing of patented drugs to ensure availability of life saving drugs at affordable prices to its people. The Controller General of Patents, Designs and Trademarks had …
Cancer-treatment drug Nexavar will soon be available at Rs. 8,880 per pack of 120 tablets. Bayer, a German multi-national, holds the patent for Nexavar (the brand name of sorafenib tosylate), which now sells at Rs.2.84 lakh. The way for such a huge reduction in the price is cleared with India …
India’s first compulsory licence worries MNC drugmakers The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany’s Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry’s anxiety …
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment. The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an …
Mumbai: In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer’s patented anti-cancer drug, Nexavar, bringing down its price by 97 %.. In the first-ever …
India has strongly opposed an anticounterfeiting trade agreement by a small group of countries including the US, Switzerland, Canada and Japan recently, which it feels will be used to stop the country's generic drug exports. Nw Delhi has said the agreement is at the behest of the multinational companies that …
Mumbai: There may soon be changes in the labelling of widely-used cholesterol lowering drugs — statins — sold in the country. The US Food and Drug Administration (FDA) warned that patients taking statins may face a “small increased risk” of higher blood-sugar levels and diabetes. Doctors here said that these …
In recent years, there has been much work done due to increasing recognition that children need better medicines. The United States of America and the European Union have adopted regulations to encourage research and development of medicines for children; the World Health Organization (WHO) has been promoting “Make medicines child …
This vaccine policy is more about spending and coverage, than about protecting children. It is not designed to enhance national public capacities for public immunization programmes, but to justify spending public money on public private partnerships (PPPs) or privately produced vaccines in the name of protection from diseases, whose incidence …
